Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRG002 in HER2-positive advanced solid tumors
NCT04941339Phase 1Unknown
- Sponsor
- Hangzhou Miracogen
- Start
- Nov 2018
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MRG002 in HER2-positive solid tumor, sponsored by Hangzhou Miracogen. Primary endpoints: Maximum Tolerated Dose, Recommended Phase II Dose up to 6 months and 1 more. Status: unknown.
02
Drugs
MRG002
03
Conditions
HER2-positive solid tumor
Beyond the preview
Go deeper on NCT04941339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04941339.